Business
Vivos Therapeutics Schedules Third Quarter 2021 Financial Results Conference Call
Call Scheduled for Monday, November 15, 2021 at 5:00 pm ET HIGHLANDS RANCH, Colo., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the
About this update from Vivos Therapeutics, Inc.
[{"type":"text","content":"Call Scheduled for Monday, November 15, 2021 at 5:00 pm ET\nHIGHLANDS RANCH, Colo., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (OSA) and snoring in adults, today announced that it plans to release financial results for the third quarter ended September 30, 2021 after market close on Monday, November 15, 2021. The Company will conduct a conference call the same day at 5:00 p.m. (Eastern Time) to review the results as well as provide an overview of the Company’s recent milestones and growth strategy. To access the conference call, please dial (888) 394-8218, or for international callers, (720) 452-9217. A replay will be available shortly after the call and can be accessed by dialing (844) 512-2921, or for international callers, (412) 317-6671. The passcode for the live call and the replay is 5806322. The replay will be available until November 29, 2021. A live webcast of the conference call can be accessed on Vivos’ website at https://vivoslife.com/investor-relations/. An online archive of the webcast will be available on the Company’s website for 30 days following the call. About Vivos Therapeutics, Inc. Vivos Therapeutics Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for adult patients suffering from mild-to-moderate obstructive sleep apnea (OSA). The Vivos treatment involves customized oral appliances and treatment protocols called the Vivos System. Vivos believes that its Vivos System oral appliance technology represents the first clinically effective non-surgical, non-invasive, non-pharmaceutical and cost-effective solution for adults with mild-to-moderate OSA. Vivos also sells orthodontic appliances for adults and children. Vivos’ oral appliances have proven effective in over 19,000 patients treated worldwide by more than 1,250 trained dentists. Combining proprietary technologies and protocols that alter the size, shape and position of the tissues that comprise a patient’s upper airway, the Vivos System opens airway space and may significantly reduce symptoms and conditions associated with ...